NANETS produces a monthly eNewsletter, Net News. Net News contains information on recent NET disease research, guidelines and resources. It also highlights NET continuing medical education (CME) programming, medical society developments, member accomplishments and news from other NET organizations. Have news to share? Contact us! Net News is a benefit of membership in NANETS. Not a member? Subscribe now!


(St. Louis, MO and Houston, TX – August 27, 2018) - Curium and RadioMedix Inc. announced an  exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission tomography (PET) diagnostic agent for patients with suspected Neuroendocrine Tumors (NETs). RadioMedix is currently engaged in Phase III clinical trials of the agent and expects to file a New Drug Application with the Food and Drug Administration in 2019. This partnership builds on the initial development work conducted by RadioMedix and will benefit from Curium’s regulatory, manufacturing, distribution, and commercial expertise."

Therapy for Pheo and Para Neuroendocrine Tumors Receives FDA Approval Following Trials at the University of Pennsylvania


On July 30, Progenics Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZEDRA (iobenguane I 131) 555 MBq/mL injection for intravenous use. AZEDRA, a radiotherapeutic, is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.  AZEDRA is the first and only approved therapy for this indication.

a

NANETS Staff enjoyed several days in Philadelphia at the 2018 SNMMI Annual Meeting in Philadelphia, PA, June 23-26. Thank you to everyone who stopped by our booth to learn more about NANETS and NET disease.